Byetta - (250MCG/ML; Injectable, Subcutaneous)

Generic Name	EXENATIDE SYNTHETIC	**Innovator**	Astrazeneca
Dosage	250MCG/ML; Injectable, Subcutaneous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.